Barton Wachs

806 total citations
15 papers, 622 citations indexed

About

Barton Wachs is a scholar working on Urology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Barton Wachs has authored 15 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Urology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Barton Wachs's work include Urinary Bladder and Prostate Research (7 papers), Hormonal and reproductive studies (5 papers) and Prostate Cancer Diagnosis and Treatment (5 papers). Barton Wachs is often cited by papers focused on Urinary Bladder and Prostate Research (7 papers), Hormonal and reproductive studies (5 papers) and Prostate Cancer Diagnosis and Treatment (5 papers). Barton Wachs collaborates with scholars based in United States, France and Canada. Barton Wachs's co-authors include Jay M. Young, Gregory D. Sides, Anne Esler, Jed Kaminetsky, Béla Dénes, Stephen M. Auerbach, Kevin T. McVary, Claus G. Roehrborn, Franklin Chu and Alex E. Finkbeiner and has published in prestigious journals such as Neurology, Cancer and Spine.

In The Last Decade

Barton Wachs

15 papers receiving 588 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barton Wachs United States 10 367 320 268 199 107 15 622
Enrico Spera Italy 12 178 0.5× 184 0.6× 148 0.6× 167 0.8× 114 1.1× 19 512
P. Bondil France 12 91 0.2× 190 0.6× 101 0.4× 117 0.6× 71 0.7× 53 454
Carlos Ary Vargas Souto Brazil 13 215 0.6× 353 1.1× 332 1.2× 98 0.5× 53 0.5× 26 612
Robert Andrianne Belgium 10 135 0.4× 167 0.5× 79 0.3× 187 0.9× 126 1.2× 62 437
Gianfranco Savoca Italy 11 186 0.5× 253 0.8× 130 0.5× 66 0.3× 65 0.6× 22 402
Robert Pickard United Kingdom 11 408 1.1× 205 0.6× 186 0.7× 253 1.3× 230 2.1× 29 664
M. Lieber United States 11 713 1.9× 128 0.4× 200 0.7× 549 2.8× 421 3.9× 15 977
Timothy Moon United States 9 544 1.5× 232 0.7× 301 1.1× 291 1.5× 193 1.8× 10 762
Albert Elion‐Mboussa United States 10 551 1.5× 529 1.7× 446 1.7× 105 0.5× 121 1.1× 13 741
Kweon Sik Min South Korea 15 408 1.1× 370 1.2× 294 1.1× 101 0.5× 271 2.5× 34 767

Countries citing papers authored by Barton Wachs

Since Specialization
Citations

This map shows the geographic impact of Barton Wachs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barton Wachs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barton Wachs more than expected).

Fields of papers citing papers by Barton Wachs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barton Wachs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barton Wachs. The network helps show where Barton Wachs may publish in the future.

Co-authorship network of co-authors of Barton Wachs

This figure shows the co-authorship network connecting the top 25 collaborators of Barton Wachs. A scholar is included among the top collaborators of Barton Wachs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barton Wachs. Barton Wachs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Shore, Neal D., Ronald Tutrone, Mitchell Efros, et al.. (2018). Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World Journal of Urology. 36(5). 801–809. 13 indexed citations
3.
Giuliano, François, Eusebio Rubio‐Aurioles, Michael Kennelly, et al.. (2008). Vardenafil Improves Ejaculation Success Rates and Self-confidence in Men With Erectile Dysfunction due to Spinal Cord Injury. Spine. 33(7). 709–715. 39 indexed citations
4.
Saltzstein, Daniel R., et al.. (2007). Complicated Urinary Tract Infections Treated with Extended-Release Ciprofloxacin with Emphasis onPseudomonas aeruginosa. Journal of Chemotherapy. 19(6). 694–702. 4 indexed citations
5.
McVary, Kevin T., Claus G. Roehrborn, Jed Kaminetsky, et al.. (2007). Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. The Journal of Urology. 177(4). 1401–1407. 286 indexed citations
6.
Roehrborn, Claus G., Kevin T. McVary, Sascha Auerbach, et al.. (2006). PD-02.08. Urology. 68. 7–8. 1 indexed citations
7.
Roehrborn, Claus, Jed Kaminetsky, Sascha Auerbach, et al.. (2006). THE EFFICACY AND SAFETY OF TADALAFIL ADMINISTERED ONCE A DAY FOR LOWER URINARY TRACT SYMPTOMS (LUTS) IN MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH). European Urology Supplements. 5(2). 196–196. 18 indexed citations
8.
Giuliano, F., Eusebio Rubio‐Aurioles, Michael Kennelly, et al.. (2006). Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology. 66(2). 210–216. 69 indexed citations
9.
McVary, Kevin T., Jed Kaminetsky, Stephen M. Auerbach, et al.. (2006). 1636: The Efficacy and Safety of Tadalafil Administered Once a Day for Lower Urinary Tract Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH). The Journal of Urology. 175(4S). 527–527. 9 indexed citations
10.
Schulman, Claude, et al.. (2005). Long‐term therapy with the dual 5α‐reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. British Journal of Urology. 97(1). 73–80. 28 indexed citations
11.
Giuliano, François, Eusebio Rubio‐Aurioles, Michael Kennelly, et al.. (2005). 538Influence of spinal cord injury severity on ejaculatory function, erectile function and tolerability of vardenafil in men with erectile dysfunction consequent to traumatic spinal cord injury. European Urology Supplements. 4(3). 137–137. 3 indexed citations
12.
Chu, Franklin, et al.. (2002). A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clinical Therapeutics. 24(11). 1902–1914. 71 indexed citations
13.
14.
Syed, A.M. Nisar, Ajmel Puthawala, Joel M. Cherlow, et al.. (1992). Temporary iridium-192 implant in the management of carcinoma of the prostate. Cancer. 69(10). 2515–2524. 56 indexed citations
15.
Wachs, Barton, et al.. (1988). Malignant Melanoma of the Renal Pelvis Presenting as a Primary Tumor. The Journal of Urology. 140(4). 812–814. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enrico Spera Breakdown of academic impact, for papers by P. Bondil Breakdown of academic impact, for papers by Carlos Ary Vargas Souto Breakdown of academic impact, for papers by Robert Andrianne Breakdown of academic impact, for papers by Gianfranco Savoca Breakdown of academic impact, for papers by Robert Pickard Breakdown of academic impact, for papers by M. Lieber Breakdown of academic impact, for papers by Timothy Moon Breakdown of academic impact, for papers by Albert Elion‐Mboussa Breakdown of academic impact, for papers by Kweon Sik Min
Rankless by CCL
2026